Loading
LMY-920 is an experimental CAR-T treatment from Luminary Therapeutics, made from a patient's own immune cells, aimed at three receptors on cancerous B cells. It is in early trials in lymphoma and myeloma.
LMY-920 is a BAFF ligand-based CAR-T cell therapy developed by Luminary Therapeutics. Two phase 1 trials sponsored by Luminary are registered: NCT05312801 in B-cell non-Hodgkin lymphoma with Case Comprehensive Cancer Center, and NCT05546723 in relapsed or refractory multiple myeloma with Cleveland Clinic and Case Western Reserve University. No results have been published.
T cells carry a chimeric antigen receptor built on the BAFF ligand, so each cell can bind three BAFF receptors on malignant B cells.
1.LMY-920 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"LMY-920" OR ABSTRACT:"LMY-920" OR TITLE:"BAFF CAR-T" OR ABSTRACT:"BAFF CAR-T" OR TITLE:"BAFF-L CAR T cells" OR ABSTRACT:"BAFF-L CAR T cells") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LMY-920, not a curated reading list.
Shares CAR-T cell therapy and the tag pipeline.
Shares CAR-T cell therapy and the tag pipeline.
Shares CAR-T cell therapy and the tag pipeline.
Shares CAR-T cell therapy and the tag pipeline.
Shares CAR-T cell therapy and the tag pipeline.
Shares CAR-T cell therapy and the tag pipeline.
Shares CAR-T cell therapy and the tag pipeline.
Shares CAR-T cell therapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/